Dr Petrylak on the Shifting Role of Avelumab Maintenance in Metastatic Urothelial Cancer

Daniel Petrylak, MD, discusses how the FDA approval of enfortumab vedotin plus pembrolizumab impacts the use of avelumab maintenance in urothelial cancer.

Related Keywords

Daniel Petrylak ,Yale School Of Medicine ,Genitourinary Oncology ,Yale School ,